Peter G. Traber M.D.
Net Worth
Last updated:
What is Peter G. Traber M.D. net worth?
The estimated net worth of Dr. Peter G. Traber M.D. is at least $2,990,047 as of 25 Sep 2023. He has earned $52,047 from insider trading and has received compensation worth at least $2,938,000 in Selecta Biosciences, Inc..
What is the salary of Peter G. Traber M.D.?
Dr. Peter G. Traber M.D. salary is $587,600 per year as Chief Medical Officer in Selecta Biosciences, Inc..
How old is Peter G. Traber M.D.?
Dr. Peter G. Traber M.D. is 70 years old, born in 1955.
What stocks does Peter G. Traber M.D. currently own?
As insider, Dr. Peter G. Traber M.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Selecta Biosciences, Inc. (SELB) | Chief Medical Officer | 451,826 | $0 | $0 |
What does Selecta Biosciences, Inc. do?
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Peter G. Traber M.D. insider trading
Selecta Biosciences, Inc.
Dr. Peter G. Traber M.D. has made 8 insider trades between 2020-2023, according to the Form 4 filled with the SEC. Most recently he sold 705 units of SELB stock worth $747 on 25 Sep 2023.
The largest trade he's ever made was exercising 40,000 units of SELB stock on 14 Dec 2020. As of 25 Sep 2023 he still owns at least 451,826 units of SELB stock.
Selecta Biosciences key executives
Selecta Biosciences, Inc. executives and other stock owners filed with the SEC:
- Dr. Carsten Brunn (54) Chief Executive Officer, Pres & Director
- Dr. Peter G. Traber M.D. (70) Chief Medical Officer